0001062993-23-018022.txt : 20230914 0001062993-23-018022.hdr.sgml : 20230914 20230914161420 ACCESSION NUMBER: 0001062993-23-018022 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230912 FILED AS OF DATE: 20230914 DATE AS OF CHANGE: 20230914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sebree Terri B CENTRAL INDEX KEY: 0001297912 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37526 FILM NUMBER: 231255248 MAIL ADDRESS: STREET 1: ZYNERBA PHARMACEUTICALS, INC. STREET 2: 80 W. LANCASTER AVENUE, SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zynerba Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001621443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260389433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 W. LANCASTER AVENUE STREET 2: SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 BUSINESS PHONE: 484-581-7505 MAIL ADDRESS: STREET 1: 80 W. LANCASTER AVENUE STREET 2: SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 FORMER COMPANY: FORMER CONFORMED NAME: Zynerba Pharmeceuticals, Inc. DATE OF NAME CHANGE: 20141003 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-09-12 0001621443 Zynerba Pharmaceuticals, Inc. ZYNE 0001297912 Sebree Terri B C/O ZYNERBA PHARMACEUTICALS, INC. 80 W. LANCASTER AVENUE, SUITE 300 DEVON PA 19333 0 1 0 0 President 0 Common Stock 2023-09-12 4 A 0 45000 A 608642 D Common Stock 2023-09-13 4 S 0 12401 1.3257 D 596241 D On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 45,000 performance-based restricted stock awards granted in a prior year. This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. /s/ Albert P. Parker, Attorney-in-Fact 2023-09-14